New approaches to treatment of metastatic bladder cancer.

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


The combination of methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) has been the standard therapy for transitional cell carcinoma for over a decade. Despite evidence that MVAC can improve outcome in comparison with single drugs or other combinations in this disease, only a small fraction of patients (less than 4%) become long-term survivors, and the regimen is quite toxic. Attempts to improve upon the MVAC regimen have partially ameliorated its toxicity, but they have not clearly improved outcome. Recently, a number of new chemotherapeutic agents have become available. This report summarizes the current experience with these agents and combinations.

Original languageEnglish
Pages (from-to)379-385
Number of pages7
JournalCurrent Oncology Reports
Issue number5
StatePublished - 2000


  • Antimetabolites, Antineoplastic/therapeutic use
  • Antineoplastic Agents, Phytogenic/therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols/administration & dosage
  • Bridged-Ring Compounds/therapeutic use
  • Carcinoma, Transitional Cell/drug therapy
  • Cisplatin/administration & dosage
  • Deoxycytidine/analogs & derivatives
  • Doxorubicin/administration & dosage
  • Gallium/therapeutic use
  • Gemcitabine
  • Humans
  • Ifosfamide/therapeutic use
  • Methotrexate/administration & dosage
  • Neoplasm Metastasis
  • Taxoids
  • Urinary Bladder Neoplasms/drug therapy
  • Vinblastine/administration & dosage


Dive into the research topics of 'New approaches to treatment of metastatic bladder cancer.'. Together they form a unique fingerprint.

Cite this